Last edition
News about "Lupin announces achievement of key milestones for "
Lupin announces achievement of key milestones for its clinical stage MEK inhibitor compound
Global pharma major Lupin Limited announced the achievement of key milestones for Lupin's MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers
Lupin Announces Achievement Of Key Milestones For | 27/05/2021 | By Darshana | 165
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members